Daxor Corporation (DXR)
Bid | 7 |
Market Cap | 37.58M |
Revenue (ttm) | 154.2K |
Net Income (ttm) | 1.69M |
EPS (ttm) | -0.09 |
PE Ratio (ttm) | -86.33 |
Forward PE | 52 |
Analyst | Strong Buy |
Ask | 8.15 |
Volume | 200 |
Avg. Volume (20D) | 7,116 |
Open | 7.77 |
Previous Close | 7.52 |
Day's Range | 7.77 - 7.77 |
52-Week Range | 6.55 - 10.00 |
Beta | -0.06 |
About DXR
Daxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing. The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for used in a broad range of medical and surgical conditions. The company was formerly known as Idant Corporation...
Analyst Forecast
According to 1 analyst ratings, the average rating for DXR stock is "Strong Buy." The 12-month stock price forecast is $25, which is an increase of 221.75% from the latest price.
Stock Forecasts
2 months ago · businesswire.com
TruLite Health Bolsters Health Equity Expertise with Expanded Leadership TeamTEMPE, Ariz.--(BUSINESS WIRE)--TruLite Health, developer of the only health equity solution to remediate clinical bias, has expanded the leadership team as the company strengthens artificial intellige...